Showing results (221-230 of 250) with videos related to
Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2024
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Caterina Gregorio, Marie Robin, et al.Blood|February 1, 2023
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromesAmer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, et al.Genes, Chromosomes & Cancer|September 25, 2018
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significanceJulie Schanz, Francesc Solé, Mar Mallo, et al.Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaBruce D Cheson, John M Bennett, Kenneth J Kopecky, et al.Leukemia|August 5, 2024
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance studyElena Crisà, Elvira Mora, Ulrich Germing, et al.Genes, Chromosomes & Cancer|September 11, 2015
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control groupFriederike Braulke, Catharina Müller-Thomas, Katharina Götze, et al.Leukemia & Lymphoma|February 28, 2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.Archives of Pathology & Laboratory Medicine|March 9, 2025
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/NeoplasmsSavanah D Gisriel, Fnu Aakash, John M Bennett, et al.Blood|September 21, 2022
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemiaEric J Duncavage, Adam Bagg, Robert P Hasserjian, et al.Pageof 25